Related Experiment Video
Updated: Jun 30, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Type I interferon pathway activation in connective tissue disease associated interstitial lung disease
Tobias M Defesche1,2, Thomas Koudstaal3, Marjan A Versnel1
1Department of Immunology, Erasmus Medical Centre, Rotterdam, Netherlands.
None:
Interstitial lung disease (ILD) underlies morbidity and mortality in connective tissue diseases (CTDs) such as systemic sclerosis. ILD encompasses a range of inflammatory and fibrotic pneumopathies, some of which manifest progressive characteristics. Up to 40% of ILDs are progressive, marked by radiologic progression, lung function decline, and increased symptoms. Immunosuppression is standard therapy for ILD, whereas antifibrotics like nintedanib are used in progressive fibrotic cases. Many patients deteriorate despite treatment, underscoring the need for biomarkers and targeted interventions. Type I interferon (IFN-I) signaling is implicated in CTD-ILD: interferon stimulated gene expression correlates with accelerated pulmonary decline and sustained IFN-I can precipitate ILD. In addition, IFN-I blocking agents like anifrolumab are under clinical investigation for CTD-ILD. This review examines IFN-I's role and therapeutic targeting in ILD.
Related Concept Videos
Chronic Inflammation: Introduction
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway
Type I Diabetes II: Pathophysiology
Inhibitors of Viral Protein Synthesis
Inflammatory Bowel Disease III: Crohn's Disease
